Suven Pharma - Operationally Muted Q4, Covid-19 Impairs Near Term Visibility: Dolat Capital

Scientists at R&D facility of Suven Pharmaceutical Ltd. (Source: Company website).

Suven Pharma - Operationally Muted Q4, Covid-19 Impairs Near Term Visibility: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Suven Pharmaceuticals Ltd. reported a muted Q4 on the operational front as it faced challenges in logistics, manpower and higher raw material prices.

Revenues grew 40% YoY (down 6% QoQ) in-line with our expectations led by sharp jump in specialty chemicals post a subdued Q3.

Led by higher base QoQ and higher input costs, the company reported gross and Ebitda margins at 65% and 36% respectively, lowest in past three years.

Profit share from Rising Pharma aided profits at Rs 831 million.

Citing the current Covid-19 situation, management has guided of 12-15% growth in top-line with Ebitda margins in the range of 35-40% for FY22.

Click on the attachment to read the full report:

Dolat Capital Suven Pharma Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.